{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:06:03Z","timestamp":1781834763660,"version":"3.54.5"},"reference-count":22,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2009,12,7]],"date-time":"2009-12-07T00:00:00Z","timestamp":1260144000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:p><jats:bold>Background and purpose:\u2002<\/jats:bold> Blepharospasm is classified as a focal dystonia, and botulinum toxin type A (BoNT\/A) has been shown to be a highly effective and well\u2010tolerated symptomatic treatment. Xeomin<jats:sup>\u00ae<\/jats:sup>, the latest addition to BoNT\/A preparations, is a purified, freeze\u2010dried BoNT\/A that is free from complexing proteins.<\/jats:p><jats:p><jats:bold>Methods and results:\u2002<\/jats:bold> In a double\u2010blind, parallel\u2010group, multicentre study, 300 patients with blepharospasm received either Xeomin<jats:sup>\u00ae<\/jats:sup> or Botox<jats:sup>\u00ae<\/jats:sup> 15\u201380\u2003U (J Neural Transm 2006; 113: 303). Both treatments produced statistically significant improvements from baseline in the Jankovic Rating Scale at week 3 (primary efficacy variable; Xeomin<jats:sup>\u00ae<\/jats:sup>: \u22122.90; Botox<jats:sup>\u00ae<\/jats:sup>: \u22122.67; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001 from baseline for both), with the difference between treatments (\u22120.23) indicating that Xeomin<jats:sup>\u00ae<\/jats:sup> was clinically non\u2010inferior to Botox<jats:sup>\u00ae<\/jats:sup>. No significant differences were found between Xeomin<jats:sup>\u00ae<\/jats:sup> and Botox<jats:sup>\u00ae<\/jats:sup> for all secondary variables. There were no clinically relevant differences between Xeomin<jats:sup>\u00ae<\/jats:sup> and Botox<jats:sup>\u00ae<\/jats:sup> in safety parameters, with 40 of 148 patients (27.0%) treated with Xeomin<jats:sup>\u00ae<\/jats:sup> reporting adverse events versus 45 of 155 patients (29.0%) treated with Botox<jats:sup>\u00ae<\/jats:sup>. The most common adverse event was ptosis (6.1% Xeomin<jats:sup>\u00ae<\/jats:sup> and 4.5% Botox<jats:sup>\u00ae<\/jats:sup>).<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Clinical evidence to date suggests that Xeomin<jats:sup>\u00ae<\/jats:sup> is an effective treatment for blepharospasm that does not differ from Botox<jats:sup>\u00ae<\/jats:sup> in terms of its potency, duration of effect or adverse reaction profile.<\/jats:p>","DOI":"10.1111\/j.1468-1331.2009.02880.x","type":"journal-article","created":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T05:51:50Z","timestamp":1260251510000},"page":"14-18","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Clinical efficacy and tolerability of Xeomin<sup>\u00ae<\/sup> in the treatment of blepharospasm"],"prefix":"10.1111","volume":"16","author":[{"given":"J.","family":"Jankovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/117.6.1457"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000163767.99354.C3"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000183055.81056.5c"},{"key":"e_1_2_6_5_2","first-page":"398","volume-title":"Botulinum Toxin. Therapeutic Clinical Practice and Science","author":"Dressler D","year":"2009"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110107"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.51.6.767"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000327601.46315.85"},{"key":"e_1_2_6_9_2","first-page":"371","article-title":"Blepharospasm: demographic and clinical survey of 250 patients","volume":"16","author":"Jankovic J","year":"1984","journal-title":"Ann Ophthalmol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.4.616"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055087.96356.BB"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22368"},{"issue":"3","key":"e_1_2_6_13_2","first-page":"A346","article-title":"Efficacy and safety of NT 201 (Botulinum neurotoxin free from complexing proteins) in blepharospasm","volume":"72","author":"Jankovic J","year":"2009","journal-title":"Neurology"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767050-00003"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-007-0768-7"},{"key":"e_1_2_6_16_2","first-page":"92","volume-title":"Botulinum Toxin. Therapeutic Clinical Practice and Science","author":"Kenney C","year":"2009"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100407"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21724"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-005-0323-3"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000311389.26145.95"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000174433.76707.8c"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2007.11.003"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02220526"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2009.02880.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2009.02880.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T11:30:56Z","timestamp":1694604656000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2009.02880.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":22,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1468-1331.2009.02880.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02880.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"2009-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}